Acelity Holdings Files $100M Common Stock IPO

Acelity Holdings, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The proposed maximum offering price is $100 million.

Underwriters are J.P. Morgan, Goldman, Sachs & Co., BofA Merrill Lynch, Morgan Stanley, Barclays, Credit Suisse, RBC Capital Markets, and UBS Investment Bank.

Financial statement: For the year ended December 31, 2014 and the six months ended June 30, 2015, we generated revenue of $1,866.3 million and $905.7 million, respectively. For the year ended December 31, 2014 and the six months ended June 30, 2014 and 2015, we generated loss from continuing operations of $235.0 million, $200.9 million and $22.2 million, respectively. We generated Adjusted EBITDA of $712.1 million, $322.0 million and $338.7 million for the year ended December 31, 2014 and the six months ended June 30, 2014 and 2015, respectively.

Acelity is a wholly-owned subsidiary of Acelity L.P. Inc., and in connection with this offering, Acelity will become the parent company of Acelity L.P. Inc.’s advanced wound care and regenerative medicine businesses.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
• ESS Tech closes $3.2M stock offering at $0.50 per share